Ariad Pharmaceuticals Inc (ARIA) Financial Statements (2024 and earlier)

Company Profile

Business Address 26 LANDSDOWNE ST
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2016
MRQ
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 242,295352,688237,179164,414
Cash and cash equivalents 230,888352,688237,179119,379
Short-term investments 11,407  45,035
Receivables 15,6868,3971,305101
Inventory, net of allowances, customer advances and progress billings 1,0969794196
Inventory 1,0969794196
Other current assets 16,12023,5786,043
Prepaid expense and other current assets3,835
Other undisclosed current assets    (6)
Total current assets: 275,197385,642244,946168,350
Noncurrent Assets
Inventory, Noncurrent 8134602,985 
Property, plant and equipment 254,082203,027108,7777,681
Intangible assets, net (including goodwill) 899939968993
Intangible assets, net (excluding goodwill) 899939968993
Restricted cash and investments 11,30811,30811,3571,038
Other undisclosed noncurrent assets 4,3932,4941,8612,131
Total noncurrent assets: 271,495218,228125,94811,843
TOTAL ASSETS: 546,692603,870370,894180,193
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 64,47645,87240,88134,193
Employee-related liabilities 25,33121,09512,77811,865
Accounts payable 17,01310,81911,3638,267
Accrued liabilities 22,13213,95816,74014,061
Debt   4,2002,115
Deferred compensation liability   2,5113,533
Other liabilities 24,32417,83015,136698
Deferred revenue and credits 23,50017,1001,800231
Customer advances and deposits  17,308
Other undisclosed current liabilities 19,984(8,112)7,6498,096
Total current liabilities: 132,28489,99872,17748,866
Noncurrent Liabilities
Long-term debt and lease obligation 200,000156,9084,9009,100
Long-term debt, excluding current maturities 200,000156,9084,9009,100
Liabilities, other than long-term debt 93,12991,54310,88811,576
Deferred revenue and credits 77,08575,505308538
Accounts payable and accrued liabilities 4,8004,700  
Deferred compensation liability, classified    1,968
Liability for uncertainty in income taxes   2,0002,200
Other liabilities 11,24411,3388,5806,870
Other undisclosed noncurrent liabilities 224,420   
Total noncurrent liabilities: 517,549248,45115,78820,676
Total liabilities: 649,833338,44987,96569,542
Equity
Equity, attributable to parent (103,141)80,801185,517112,851
Common stock 190187186167
Additional paid in capital 1,338,5851,299,3941,238,859890,499
Accumulated other comprehensive income (loss) 3,835(4,185)(1,535)20
Accumulated deficit (1,445,751)(1,214,595)(1,051,993)(777,835)
Total equity: (103,141)80,801185,517112,851
Other undisclosed liabilities and equity  184,62097,412(2,200)
TOTAL LIABILITIES AND EQUITY: 546,692603,870370,894180,193

Income Statement (P&L) ($ in thousands)

9/30/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues 118,804105,41245,561558
Revenue, net 112,52755,72045,238 
Cost of revenue
(Cost of Goods and Services Sold)
 (2,114)(5,224)(17,212)(145)
Gross profit: 116,690100,18828,349413
Operating expenses (336,080)(265,607)(319,127)(205,618)
Other undisclosed operating income 2,1145,22417,212145
Operating loss: (217,276)(160,195)(273,566)(205,060)
Nonoperating expense (17,274)(1,777)(153)(15,812)
Investment income, nonoperating 8285130(15,684)
Gain (loss), foreign currency transaction, before tax 7931,445(130)71
Interest and debt expense (18,149)(8,075)(153)(199)
Other undisclosed income from continuing operations before equity method investments, income taxes 18,1498,075153 
Loss from continuing operations before income taxes: (234,550)(161,972)(273,719)(221,071)
Income tax expense (benefit) 3,394(630)(439) 
Loss from continuing operations: (231,156)(162,602)(274,158)(221,071)
Loss before gain (loss) on sale of properties: (231,156)(162,602)(274,158)(221,071)
Net loss: (231,156)(162,602)(274,158)(221,071)
Other undisclosed net income attributable to parent    199
Net loss available to common stockholders, diluted: (231,156)(162,602)(274,158)(220,872)

Comprehensive Income ($ in thousands)

9/30/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss: (231,156)(162,602)(274,158)(221,071)
Other comprehensive income (loss) 8,020(2,650)(1,555)20
Comprehensive loss: (223,136)(165,252)(275,713)(221,051)
Other undisclosed comprehensive income, net of tax, attributable to parent    199
Comprehensive loss, net of tax, attributable to parent: (223,136)(165,252)(275,713)(220,852)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: